Introduction
Heart failure (HF) affects over 26 million people worldwide and is associated with high morbidity and mortality. 1 Patients with HF are differentiated according to measurements of left ventricular ejection fraction (LVEF); patients with LVEF ≤ 40% are considered to have HF with reduced ejection fraction (HFrEF) and those with LVEF > 40% are considered to have HF with preserved ejection fraction (HFpEF). LVEF of > 40% to < 50% is considered to be HFpEF in many clinical trials 2 and registries, 3, 4 although more recently the term HF with mid-range ejection fraction was introduced to categorise this group separately. 5 HFrEF and HFpEF differ in several aspects including co-morbidities and responses to treatment. 5 However, exercise intolerance, which can manifest as dyspnoea or fatigue, is a cardinal symptom of HF that affects patients regardless of the underlying LVEF and leads to impairment in physical functioning and quality of life. 5 -7 Improving HF symptoms and improving the activity of daily living, such as exercise capacity, continue to be unmet medical needs in patients with HFrEF and HFpEF.
Empagliflozin is a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor used in the treatment of type 2 diabetes mellitus (T2DM). In the EMPA-REG OUTCOME ® trial in patients with T2DM and established cardiovascular disease, empagliflozin added to standard of care reduced the risk of cardiovascular death by 38%, hospitalisation for HF by 35% and all-cause mortality by 32% compared to placebo. 8 Patients with HF comprised 10% of the EMPA-REG OUTCOME ® trial population, and irrespective of the presence of HF at baseline in those patients, the reductions in risk of these outcomes were observed early and were consistent. 9 The mechanisms responsible for the cardiovascular benefits of empagliflozin remain to be fully elucidated. Empagliflozin reduces renal glucose reabsorption, leading to increased urinary excretion of glucose, sodium and water. 10, 11 This leads to a reduction in plasma volume, 12 reflected by increases in haematocrit and haemoglobin 13, 14 and reductions in arterial stiffness and vascular resistance 15 in patients with T2DM. It has been suggested that treatment with empagliflozin may lead to a shift in metabolism from fat and glucose oxidation to a more energy-efficient fuel such as ketones. 16 In patients with T2DM, empagliflozin is associated with weight loss 8, 17 and reductions in adiposity markers 17 in addition to reductions in systolic and diastolic blood pressure without an increase in heart rate. 8, 18 HFpEF is associated with obesity, hypertension, and anaemia, and consequently with ventricular and arterial stiffness, increased cardiac workload and oxygen consumption, and reduced cardiac oxygen supply, leading to reduced exercise tolerance. 19 The combination of positive effects of empagliflozin on several of these factors could potentially improve exercise capacity and symptoms associated with congestion in patients with HFpEF, with or without diabetes. Patients with HFrEF are likely to benefit from the same combination of effects, particularly a reduction in congestion by osmodiuresis.
The • Heart failure diagnosed ≥3 months before screening, and currently in NYHA class II-IV. • Reduced ejection fraction, defined as LVEF ≤ 40% (echocardiography) at screening per local reading under stable conditions. • 6MWT distance of ≤ 350 m at screening and baseline.
Table 2 Key inclusion and exclusion criteria for the EMPERIAL-Reduced trial
• Elevated NT-proBNP (> 450 pg/mL for patients without atrial fibrillation; > 600 pg/mL for patients with atrial fibrillation) at screening. • On medical therapy for heart failure consistent with prevailing cardiovascular guidelines at a stable dose for ≥ 4 weeks prior to screening, except for diuretics which must have been stable for ≥ 2 weeks prior to screening. • Clinically stable at randomisation with no signs of heart failure decompensation (investigator's judgement).
• Myocardial infarction a , coronary artery bypass graft, or other major cardiovascular surgery, stroke, or transient ischaemic attack within 90 days prior to screening. 
Study plan
In both trials, following a screening period of 4 days to 3 weeks, eligible patients with chronic, stable HF will be randomised 1:1 to receive empagliflozin 10 mg or placebo once daily for 12 weeks (Figure 1 ). Randomisation will be performed in blocks using an Interactive Response Technology system without stratification. Patients will be required to return for study visits at week 6 and week 12, and for a follow-up visit 7-14 days after the last dose of trial medication. Patients who prematurely discontinue trial medication will be asked to return as soon as possible for an early . 
Measurements
Visits at baseline, week 6 and week 12 (and the early discontinuation visit, if applicable) will include measurements of the following: 6MWT distance, Kansas City Cardiomyopathy Questionnaire (KCCQ), 20 Chronic Heart Failure Questionnaire Self-Administered Standardised format (CHQ-SAS), 21 Clinical Congestion Score (based on a summary score of three items: orthopnoea, jugular venous distention, and oedema), Patient Global Impression of Severity of HF symptoms and dyspnoea, Patient Global Impression of Change in HF symptoms and dyspnoea, Clinician Global Impression of Severity of HF, and N-terminal pro-brain natriuretic peptide (NT-proBNP). The 6MWT will be performed at screening, baseline, week 6, week 12, and the early discontinuation visit (if applicable). At baseline and at week 12, two 6MWTs will be performed at least 1 h apart to increase reliability and reduce variability. The distances from both tests will be recorded and the largest distance measured will be used for analysis. Screening and baseline measurements will be used to assess eligibility. The 6MWT visit should be preferably performed at same time of day at each visit to minimise intraday variability. The 6MWT protocol used in this trial is based on guidelines from the American Thoracic Society. 22 A summary of study assessment timings is available in Appendix 3.
Endpoints
The primary endpoint in the EMPERIAL-Preserved and EMPERIAL-Reduced trials is the change from baseline in 6MWT distance at week 12. The key secondary endpoints in both trials are the change from baseline in KCCQ total symptom score at week 12 and the change from baseline in CHQ-SAS dyspnoea score at week 12. Other secondary endpoints are: change from baseline in 6MWT distance at week 6; change from baseline in Clinical Congestion Score at week 12; change from baseline in Patient Global Impression of Severity of HF symptoms at week 12; change from baseline in Patient Global Impression of Severity of dyspnoea at week 12; Patient Global Impression of Change in HF symptoms at week 12; Patient Global Impression of Change in dyspnoea at week 12; and change from baseline in NT-proBNP at week 12. A summary of study endpoints is shown in Appendix 4.
Safety will be assessed based on adverse events reported throughout the study and up to 7 days after the last dose of study medication [ 
Study oversight
The trials were jointly designed by representatives of Boehringer Ingelheim, the sponsor of the trial, and the academic investigators who are members of the Executive Committee. The Executive Committee, which includes academic experts and sponsor representatives, supervised the trial designs and will supervise the trial operation. A Steering Committee consisting of the Executive Committee, National Coordinators and sponsor representatives will support the investigators in trial conduct, specifically recruitment and retention. An independent Data Monitoring Committee will evaluate safety data at regular intervals. The committee members are the same for both trials and are listed in Appendix 5.
Statistical considerations

Sample size
In each trial, a sample size of 150 patients per randomised treatment group is required to provide a 90% power to detect a 30 m treatment difference between empagliflozin and placebo in the change from baseline in 6MWT distance (considered to be clinically meaningful in patients with HF 23 ), assuming a standard deviation of 72 m and worst-case imputation of missing data for 5% of patients.
Statistical methodology
The null hypotheses of no effect of empagliflozin vs. placebo for the primary and key secondary endpoints will be tested in the following procedure to control the overall probability of a two-sided type 1 error at 0.05. If the primary analysis of the primary endpoint reveals a significant result in favour of empagliflozin, both key secondary endpoints will be tested. For adjustment of multiplicity of the tests of the two key secondary endpoints, a Hochberg procedure will be followed. If the largest P-value of the primary analysis of the two key secondary endpoints is below 5%, both null hypotheses of the key secondary endpoints will be rejected. Otherwise, if the smaller P-value of the primary analysis of the two key secondary endpoints is below 2.5%, only the corresponding null hypothesis can be rejected. If the primary hypothesis is not rejected (i.e. if the primary analysis of change from baseline in 6MWT distance at week 12 is not met in favour of empagliflozin), the tests of the key secondary endpoints will be conducted in an exploratory fashion.
The primary analyses of primary and both key secondary endpoints will be a Wilcoxon rank test, including patients with missing data via a worst-case imputation. Patients with an available week 12 measurement, regardless of whether on or off-treatment, will be ranked based on change from baseline at week 12. In all other cases, a worst-case imputation will be performed in the following manner: all imputed data due to missing data will be ranked lower than measured values. Patients who do not have a clinical event (death, serious adverse event or any adverse event leading to discontinuation) and have a value at week 6 will be ranked by their values. Patients who do not have a clinical event and have no valid post-baseline value will be ranked below. Patients who have a clinical event will be given a lower rank and death is ranked below any other clinical event by time to death from randomization. This imputation strategy will be used for all confirmatory analyses (i.e. primary analyses of primary and key secondary endpoints). For estimation of effect, the non-parametric Hodges-Lehmann estimate for the median difference will be calculated. Efficacy analyses will be conducted in all randomised patients. Sensitivity analyses for the primary and key secondary endpoints will include mixed model repeated measures (MMRM) analyses with the baseline value of the endpoint in question as a covariate, without imputation of missing values. Several exploratory subgroup analyses are pre-specified in the statistical analysis plan including an analysis by diabetes status (diabetes vs. no diabetes).
Change from baseline in 6MWT distance at week 6 will be analysed using the same model as the primary analysis of the endpoint. The change from baseline to week 12 in Clinical Congestion Score will be evaluated using an MMRM analysis with treatment as a fixed effect and baseline Clinical Congestion Score as a linear covariate. The proportion of patients in every category of Global Impression of Change at week 12 and the proportions of patients categorised by the shift in Patient Global Impression of Severity scores between baseline and week 12 will be evaluated using Cochran-Mantel-Haenszel test. Change from baseline in NT-proBNP at week 12 (after log-transformation) will be evaluated using an MMRM with baseline log-transformed NT-proBNP as a covariate, without imputation of missing values. Safety will be analysed descriptively in patients treated with ≥ 1 dose of study drug. No interim analysis is planned.
. 
Discussion
HFpEF and HFrEF have a significant impact on the physical functioning and well-being of patients 6, 7, 24 in addition to a substantial risk of mortality and hospitalisation. 25, 26 Exercise capacity appears to correlate with quality of life outcomes in patients with HF, but to a greater extent in patients with HFpEF; in patients with HFrEF, raised left atrial pressure may play a greater role in determining exercise capacity. Recommendations for the treatment of HFrEF include use of angiotensin-converting enzyme inhibitors, angiotensin receptor antagonists, an angiotensin receptor-neprilysin inhibitor, beta-blockers, and mineralocorticoid receptor antagonists, all of which have been shown to reduce mortality in patients with HFrEF. 5 However, HFrEF remains associated with symptom burden, reduced exercise capacity and impaired physical functioning. 6, 24 Patients with HFpEF tend to be older, more often female, and more likely to have a history of hypertension and atrial fibrillation than patients with HFrEF. 5 According to the current guidelines, no treatment has been shown to reduce mortality in patients with HFpEF. 5 A recent meta-analysis by Zheng et al. 2 reported that beta-blockers may reduce cardiovascular mortality, though meta-analyses of drug interventions have shown no improvement in exercise capacity or functional outcomes in these patients, with only limited improvement in patient quality of life. 2, 27 The management of HFpEF involves control of congestive symptoms, usually with diuretics, and the treatment of co-morbidities. 5 In the absence of effective treatments to reduce mortality, alleviating symptoms and improving patient well-being may be important goals in the management of patients with HFpEF, 5 and there is an unmet medical need for treatments that can improve quality of life in these patients.
Analyses have suggested that the effects of the SGLT2 inhibitor empagliflozin on mortality and HF hospitalisation in the EMPA-REG OUTCOME trial were independent of its glucose-lowering effects, 9, 13, 28 and several of the other mechanisms proposed to explain the cardiovascular risk reduction with empagliflozin may be beneficial to patients with HF regardless of the presence of diabetes. 29 Further, the effects of empagliflozin with the potential to improve exercise capacity in patients with HF are unlikely to differ by LVEF. 29 The long-term effects of empagliflozin on cardiovascular death and hospitalisation for HF across the spectrum of patients with HFpEF and HFrEF (with and without diabetes) are being investigated in the EMPEROR-Preserved (NCT03057951) and EMPEROR-Reduced trials (NCT03057977), respectively. Together, these trials will provide insight into the potential of empagliflozin in the treatment of patients with HFpEF and HFrEF.
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Appendix 1. Inclusion and exclusion criteria for the EMPERIAL-Preserved trial Inclusion criteria
All of the following criteria needed to be met:
• ≥ 18 years of age.
• Written informed consent prior to admission to the trial.
• Women of child-bearing potential must agree to use birth control measures with a failure rate of < 1% per year during the treatment period of the study. • Heart failure diagnosed ≥ 3 months before screening, and currently in New York Heart Association class II-IV. • Presence of ≥ 1 of the following: -Structural heart disease (left atrial enlargement and/or left ventricular hypertrophy) documented by echocardiogram at screening -Hospitalisation for heart failure within previous 12 months prior to screening.
• Preserved ejection fraction, defined as left ventricular ejection fraction (LVEF) > 40% (echocardiography) at screening per local reading and no prior measurement of LVEF ≤ 40% under stable conditions. • 6-min walk test (6MWT) distance of ≤ 350 m at screening and baseline. • Elevated N-terminal pro-brain natriuretic peptide (> 300 pg/mL for patients without atrial fibrillation; > 600 pg/mL for patients with atrial fibrillation).
• If oral diuretics are prescribed to control symptoms, the dose must have been stable for ≥ 2 weeks prior to study entry. • Clinically stable at randomisation with no signs of heart failure decompensation (investigator's judgement).
Exclusion criteria
• training programme within 1 month prior to screening or planned to start one during the course of this trial. • Heart transplant recipient or listed for heart transplant.
• Cardioverter-defibrillator implantation within 1 month prior to screening or planned during the course of the trial. • Implanted cardiac resynchronisation therapy.
• Cardiomyopathy based on infiltrative diseases (e.g. amyloidosis), accumulation diseases (e.g. haemochromatosis, Fabry disease), muscular dystrophies, cardiomyopathy with reversible causes (e.g. stress cardiomyopathy), hypertrophic obstructive cardiomyopathy, or known pericardial constriction. • Any severe (obstructive or regurgitant) valvular heart disease that either represents a risk for the conduct of the 6MWT or is expected to lead to surgery during the trial (investigator's opinion). • Chronic pulmonary disease (i.e. with known forced expiratory volume in 1 s < 50% requiring home oxygen, or oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease (investigator's opinion), or primary pulmonary arterial hypertension). • Indication of liver disease, defined by serum levels of either alanine aminotransferase (SGPT), aspartate aminotransferase (SGOT), or alkaline phosphatase above 3 x upper limit of normal as determined at screening. • Haemoglobin < 9 g/dL at screening. • History of ketoacidosis.
• Major surgery (major according to investigator's opinion) performed within 90 days prior to screening, or scheduled major elective surgery (e.g. hip or knee replacement) during the course of the trial. • Gastrointestinal surgery/disorder that could interfere with trial medication absorption in the investigator's opinion.
• Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of uterine cervix or low-risk prostate cancer. • Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial. • Current use or prior use of a sodium-glucose co-transporter 2 (SGLT2) inhibitor or combined SGLT1 and 2 inhibitor within 12 weeks prior to screening or during screening period until randomisation. Discontinuation of an SGLT2 inhibitor or combined SGLT1 and 2 inhibitor for the purposes of study enrolment is not permitted. • Treatment with i.v. iron therapy or erythropoietin within 3 months prior to screening. • Currently enrolled in another investigational device or drug trial, or less than 30 days since ending another investigational device or drug trial(s), or receiving other investigational treatment(s). Patients participating in a purely observational trial will not be excluded. • Known allergy or hypersensitivity to empagliflozin or other SGLT2 inhibitors. • Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial patient or unlikely to complete the trial. • Women who are pregnant, nursing, or who plan to become pregnant while in the trial. • Any other clinical condition that would jeopardise patients safety while participating in this trial, or may prevent the subject from adhering to the trial protocol.
Appendix 2. Inclusion and exclusion criteria for the EMPERIAL-Reduced trial Inclusion criteria
• Written informed consent prior to admission to the trial. • Symptomatic bradycardia or second or third degree heart block without a pacemaker after adjusting beta-blocker therapy, if appropriate. • Chronic pulmonary disease (i.e. with known forced expiratory volume in 1 s < 50% requiring home oxygen, or oral steroid therapy or hospitalisation for exacerbation within 12 months, or significant chronic pulmonary disease (investigator's opinion), or primary pulmonary arterial hypertension. • Indication of liver disease, defined by serum levels of either alanine aminotransferase (SGPT), aspartate aminotransferase (SGOT), or alkaline phosphatase above 3 x upper limit of normal as determined at screening. • Haemoglobin < 9 g/dL at screening. • History of ketoacidosis.
• Major surgery (major according to investigator's opinion) performed within 90 days prior to screening, or scheduled major elective surgery (e.g. hip or knee replacement) during the course of the trial. • Current use or prior use of a sodium-glucose co-transported 2 (SGLT2) inhibitor or combined SGLT1 and 2 inhibitor within 12 weeks prior to screening or during screening period until randomisation. Discontinuation of an SGLT2 inhibitor or combined SGLT1 and 2 inhibitor for the purposes of study enrolment is not permitted. • Treatment with i.v. iron therapy or erythropoietin within 3 months prior to screening. • Currently enrolled in another investigational device or drug trial, or less than 30 days since ending another investigational device or drug trial(s), or receiving other investigational treatment(s). Patients participating in a purely observational trial will not be excluded. • Known allergy or hypersensitivity to empagliflozin or other SGLT2 inhibitors. • Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable trial patient or unlikely to complete the trial. • Women who are pregnant, nursing, or who plan to become pregnant while in the trial. • Any other clinical condition that would jeopardise patients safety while participating in this trial, or may prevent the subject from adhering to the trial protocol.
Appendix 4. Endpoints in the EMPERIAL-Preserved and EMPERIAL-Reduced trials
Primary endpoint • Change from baseline in 6-min walk test distance at week 12 Key secondary endpoints • Change from baseline in Kansas City Cardiomyopathy Questionnaire total symptom score at week 12 • Change from baseline in Chronic Heart Failure Questionnaire Self-Administered Standardized format dyspnoea score at week 12
Other secondary endpoints
Week 6
• Change from baseline in 6MWT distance at week 6
Week 12
• Change from baseline in Clinical Congestion Score at week 12 • Change from baseline in Patient Global Impression of Severity of heart failure symptoms at week 12 • Change from baseline in Patient Global Impression of Severity of dyspnoea at week 12 • Patient Global Impression of Change in heart failure symptoms at week 12 • Patient Global Impression of Change in dyspnoea at week 12 • Change from baseline in N-terminal pro-brain natriuretic peptide at week 12
